Zai Lab Reports 81.8% ORR in First-Line ES-SCLC Study
Zoci 1.6 mg/kg plus atezolizumab showed a confirmed 81.8% ORR (27/33) and an estimated 6-month PFS rate of 81.9%; related Grade >3 adverse events were 9.1%. A global randomized Phase 3 study is expected to start by year-end 2026.